Snapshot from Aug 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Dyne Therapeutics upsized public offering
Business equity offering

Dyne Therapeutics upsized public offering

Analysis based on 6 articles · First reported Jul 21, 2026 · Last updated Jul 23, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The offering provides Dyne Therapeutics with substantial capital to fund its research and development pipeline, potentially accelerating drug development timelines. The successful upsized offering signals strong investor demand for Dyne's stock, which may support its share price in the near term.

Biotechnology Pharmaceuticals
Event Summary

Dyne Therapeutics, Inc. (Nasdaq: DYN) completed an upsized underwritten public offering of 21,045,000 shares of common stock at $20.50 per share, including full exercise of the underwriters' option to purchase additional shares. Gross proceeds were approximately $431.4 million. The offering was managed by Morgan Stanley, Jefferies, Evercore, LifeSci Capital, Raymond James, and JonesTrading. The company plans to use the proceeds to advance its clinical programs for Duchenne muscular dystrophy and myotonic dystrophy type 1, as well as preclinical programs for other neuromuscular diseases.

Key Actions
90 Dyne Therapeutics priced upsized offering
30 Dyne Therapeutics granted underwriter option
Entities Involved
stock
Dyne Therapeutics
Dyne raised $431.4 million through the offering, strengthening its balance sheet to fund clinical programs.
Importance 100.0 Sentiment 30.0
stock
Morgan Stanley
Acted as joint book-running manager, earning underwriting fees and reinforcing its role in biotech equity offerings.
Importance 60.0 Sentiment 10.0
priv
Jefferies
Acted as joint book-running manager, earning underwriting fees and reinforcing its role in biotech equity offerings.
Importance 60.0 Sentiment 10.0
priv
Evercore
Acted as joint book-running manager, earning underwriting fees and reinforcing its role in biotech equity offerings.
Importance 60.0 Sentiment 10.0
priv
LifeSci Capital
Acted as joint book-running manager, earning underwriting fees.
Importance 40.0 Sentiment 10.0
stock
Raymond James Financial
Acted as joint book-running manager, earning underwriting fees.
Importance 40.0 Sentiment 10.0
priv
JonesTrading
Acted as lead manager, earning underwriting fees.
Importance 20.0 Sentiment 5.0
govactor
United States — United States Securities and Exchange Commission
The offering was conducted under an effective shelf registration statement filed with the SEC.
Importance 10.0 Sentiment 0.0
Relationships
Morgan Stanley related ↔ Jefferies
Morgan Stanley related ↔ Evercore
Morgan Stanley related ↔ Raymond James Financial
Morgan Stanley related ↔ United States — United States Securities and Exchange Commission
Jefferies related ↔ Evercore
Jefferies related ↔ United States — United States Securities and Exchange Commission
Evercore related ↔ United States — United States Securities and Exchange Commission
LifeSci Capital related ↔ United States — United States Securities and Exchange Commission
Raymond James Financial related ↔ United States — United States Securities and Exchange Commission
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.